Technical Analysis for ORGO - Organogenesis Holdings Inc.

Grade Last Price % Change Price Change
grade D 4.21 0.72% 0.03
ORGO closed up 0.72 percent on Wednesday, June 3, 2020, on 1.67 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ORGO trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 0.72%
Wide Bands Range Expansion 0.72%
Upper Bollinger Band Touch Strength 0.72%
Calm After Storm Range Contraction 6.85%
Upper Bollinger Band Walk Strength 6.85%
Inside Day Range Contraction 6.85%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Medicine Clinical Medicine Organ Systems Surgery Regenerative Medicine Burns Sports Medicine Injuries Pipeline Products Wound Acute Pain Medicine Products Surgical Treatment Wound Care Products Diabetic Foot Ulcers First Aid Surgical Applications Venous Leg Ulcers

Is ORGO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.35
52 Week Low 2.4722
Average Volume 160,515
200-Day Moving Average 4.92
50-Day Moving Average 3.46
20-Day Moving Average 3.64
10-Day Moving Average 3.82
Average True Range 0.51
ADX 22.72
+DI 28.04
-DI 8.16
Chandelier Exit (Long, 3 ATRs ) 3.26
Chandelier Exit (Short, 3 ATRs ) 4.55
Upper Bollinger Band 4.43
Lower Bollinger Band 2.85
Percent B (%b) 0.86
BandWidth 43.53
MACD Line 0.18
MACD Signal Line 0.09
MACD Histogram 0.088
Fundamentals Value
Market Cap 39.06 Million
Num Shares 9.28 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 105.25
Price-to-Sales 0.00
Price-to-Book 18.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.95
Resistance 3 (R3) 5.00 4.81 4.83
Resistance 2 (R2) 4.81 4.62 4.78 4.79
Resistance 1 (R1) 4.51 4.50 4.66 4.46 4.74
Pivot Point 4.31 4.31 4.39 4.29 4.31
Support 1 (S1) 4.02 4.13 4.17 3.96 3.68
Support 2 (S2) 3.82 4.01 3.79 3.63
Support 3 (S3) 3.52 3.82 3.59
Support 4 (S4) 3.47